AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

XGN · NASDAQ · Medical - Diagnostics & Research

Exagen

Develops AVISE tests for diagnosis and monitoring of autoimmune disease.

$7.39

After-hours close+0.01 (+0.14%)

At close$7.38(−1.86%)

Something off on this page? Send us feedback.

Profile

Exagen Inc.XGNHealth Care

Develops and commercializes AVISE-branded diagnostic tests for complex rheumatic and autoimmune conditions. AVISE CTD is the flagship product, using CB-CAPs technology to support differential diagnosis, prognosis, and disease monitoring.

Develops and commercializes AVISE-branded diagnostic tests for clinicians managing complex rheumatic and autoimmune conditions. Its flagship AVISE CTD test supports differential diagnosis of those conditions; the portfolio also addresses prognosis and ongoing disease monitoring.

Built around CB-CAPs technology, the testing franchise is intended to help clinicians reach timely assessments and guide management of chronic autoimmune disease. AVISE CTD has been the commercial anchor since its 2012 launch, and recent product updates added rheumatoid-arthritis offerings. The business is headquartered in Vista, California, and its core activity remains the design and commercialization of autoimmune diagnostic tests.

Company facts

CEOJohn Aballi

ListedSep 19, 2019

ExchangeNASDAQ

HeadquartersVista, CA

CountryUnited States

Employees216

CIK0001274737

ISINUS30068X1037

Key statistics

Market cap$178.5M

EPS (ttm)−$0.8200

P/E (ttm)−9.01

ROE-121.6%

P/B14.62

P/S2.51

Dividend yield—

Beta2.28vs XLV 0.48

Year to date +22.2% · Average volume (30d) 400.9K

Analysts

Price target, next 12 months$8.00+8.3%Median of 10 analysts · vs the Aug 28 close

ConsensusBuy10 of 10 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.39

High$10.00+35.3%

Median$8.00+8.3%

Low$8.00+8.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Jun 24, 2026	Roth Capital	Initiate	Buy		$8
May 12, 2026	BTIG	Reiterate	Buy	$9	$8
Apr 20, 2026	Canaccord Genuity	Reiterate	Buy	$15	$8
Mar 11, 2026	UBS	Target			$10
Mar 10, 2026	BTIG	Reiterate	Buy	$10	$9

Earnings

EPS

Estimate−$0.19

ReportedDue Nov 3, 2026

Revenue

Estimate$18.3M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 4, 2026Q2 FY26	−$0.19	−$0.13	+32.1%	$17.8M	$19.9M	+12.0%	+37.82%
May 11, 2026Q1 FY26	−$0.24	−$0.17	+29.2%	$16.4M	$17.3M	+5.5%	−6.78%
Mar 10, 2026Q4 FY25	−$0.20	−$0.20	0.0%	$16.6M	$16.6M	+0.4%	−4.31%
Nov 4, 2025Q3 FY25	−$0.13	−$0.19	−46.2%	$16.5M	$17.2M	+4.3%	−4.09%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$15.5M	$17.2M	$17.2M	$16.6M	$17.3M	$19.9M
Gross profit	$9.1M	$10.4M	$10.1M	$9.2M	$10.2M	$12.2M
Operating income	−$3.4M	−$2.6M	−$3.1M	−$5.0M	−$3.4M	−$1.7M
Net income	−$3.8M	−$4.4M	−$7.1M	−$4.7M	−$4.0M	−$3.2M
Diluted EPS	−$0.20	−$0.21	−$0.31	−$0.21	−$0.17	−$0.13
Gross margin	58.9%	60.4%	58.4%	55.4%	59.0%	61.3%
Operating margin	-21.7%	-15.3%	-18.0%	-29.9%	-19.7%	-8.6%

Fiscal years (4-quarter sums)FY21 $48.3M · FY22 $45.6M · FY23 $52.5M · FY24 $55.6M · FY25 $66.6M

Revenue by product · Q2 FY26

Reportable Segment$19.9M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $24.6M · Total debt $25.5M · Total assets $51.9M · Shareholders' equity $12.2M

Dividends

No dividends on record.

Ownership

Institutions 40.04%9.67M sharesInsiders 4.89%1.18M sharesOther 55.07%13.30M shares

Shares outstanding 24.16M · Float 13.81M · 57.2% free float

A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Chernett Jorey	2.41M	9.90%	13G	May 20, 2026
NMSIC Co-Investment Fund, L.P.	1.37M	6.04%	13G	Feb 11, 2026
Parian Ultreia LP	1.29M	5.30%	13G	May 27, 2026
Cowen Financial Products LLC	891.4K	5.00%	13G	May 12, 2025
John Aballi · director, officer: President and CEO	839.8K	3.48%	Form 4	Mar 16, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Mar 3, 2026	John Aballi	director, officer: President and CEO	−15,698	$3.62
Feb 24, 2026	Jeffrey G. Black	officer: Chief Financial Officer	−1,584	$3.61
Feb 24, 2026	John Aballi	director, officer: President and CEO	−11,430	$3.61
Oct 16, 2025	John Aballi	director, officer: President and CEO	−31,787	$11.82
Sep 2, 2025	Jeffrey G. Black	officer: Chief Financial Officer	−20,466	$9.79